General

2024-01-20T18:07:25+00:00

CARA THERAPEUTICS RECRUITING STUDIES: • CR845-310301 – CKD/Pruritus This is a clinical trial testing oral difelikefalin to see if it helps reduce the intensity of itching and the impact that itching has on your quality of life. The study spans a duration of 16 weeks to 1 [...]

Endocrinology

2024-01-04T17:47:51+00:00

CORCEPT THERAPUETICS RECRUITING STUDIES: • CORT125134-456 (GRADIENT) – Hypercortisolism The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination [...]

Diabetes

2024-01-20T18:13:29+00:00

BIOMEA FUSION, INC. RECRUITING STUDIES: • COVALENT-112 – Type 1 Diabetes: COVALENT-112 is a Phase 2 trial designed to examine beta-cell function, insulin sensitivity, and both glucose and lipid metabolism in participants with T1D treated with BMF-219. The study will last around 1 year. Those meeting the eligibility [...]

Renal Disease

2023-12-15T18:45:27+00:00

CARA THERAPUETICS RECRUITING STUDIES: • CR845-310301 – CKD/Pruritus This is a clinical trial testing oral difelikefalin to see if it helps reduce the intensity of itching and the impact that itching has on your quality of life. The study spans a duration of 16 weeks to 1 [...]

Cardiovascular Disease

2024-01-04T17:19:04+00:00

NOVO NORDISK RECRUITING STUDIES: • EX6018-4758 (ZEUS) – Cardiovascular risk/CKD/Inflammation This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. The study’s duration will last up to 4 [...]

Go to Top